Ahmedabad-based Nirma is set to acquire Glenmark Life Sciences (GLS), a subsidiary of Glenmark Pharma, for Rs 5,652 crore. This move marks Nirma's entry into the active pharmaceutical ingredient (API) sector and expands its pharmaceutical portfolio, which includes injectables, parentals, and ophthalmic products. GLS specializes in developing APIs for various therapeutic segments.from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/x1qZLsI
